Fevertree Drinks PLC (FQVTY)

Theseus Pharmaceuticals Income Statement

Financials in millions GBP. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	368.5	364.4	344.3	311.1	252.1
Revenue Growth (YoY)	1.13%	5.84%	10.67%	23.40%	-3.23%
Cost of Revenue	230.1	247.4	225.5	180.2	135.8
Gross Profit	138.4	117	118.8	130.9	116.3
Selling, General & Admin	96	88.2	83.5	68.7	61.1
Operating Expenses	105.6	96.2	88.2	75.3	65
Operating Income	32.8	20.8	30.6	55.6	51.3
Interest Expense	-0.6	-0.6	-0.4	-0.3	-0.2
Interest & Investment Income	3.3	2	0.8	0.3	0.5
EBT Excluding Unusual Items	35.5	22.2	31	55.6	51.6
Pretax Income	35.5	22.2	31	55.6	51.6
Income Tax Expense	11.1	6.8	6.1	11	9.9
Net Income	24.4	15.4	24.9	44.6	41.7
Net Income to Common	24.4	15.4	24.9	44.6	41.7
Net Income Growth	58.44%	-38.15%	-44.17%	6.95%	-28.72%
Shares Outstanding (Basic)	117	117	117	117	116
Shares Outstanding (Diluted)	117	117	117	117	117
Shares Change (YoY)	0.16%	0.04%	-0.05%	0.19%	0.03%
EPS (Basic)	0.21	0.13	0.21	0.38	0.36
EPS (Diluted)	0.21	0.13	0.21	0.38	0.36
EPS Growth	58.19%	-38.18%	-44.17%	6.79%	-28.85%
Free Cash Flow	66.9	-6.4	3.9	43.2	35.5
Free Cash Flow Per Share	0.57	-0.06	0.03	0.37	0.30
Dividend Per Share	0.170	0.166	0.163	0.160	0.157
Dividend Growth	1.98%	2.02%	2.00%	1.98%	3.98%
Gross Margin	37.56%	32.11%	34.51%	42.08%	46.13%
Operating Margin	8.90%	5.71%	8.89%	17.87%	20.35%
Profit Margin	6.62%	4.23%	7.23%	14.34%	16.54%
Free Cash Flow Margin	18.15%	-1.76%	1.13%	13.89%	14.08%
EBITDA	37.8	24.9	34.7	59.5	54.5
EBITDA Margin	10.26%	6.83%	10.08%	19.13%	21.62%
D&A For EBITDA	5	4.1	4.1	3.9	3.2
EBIT	32.8	20.8	30.6	55.6	51.3
EBIT Margin	8.90%	5.71%	8.89%	17.87%	20.35%
Effective Tax Rate	31.27%	30.63%	19.68%	19.78%	19.19%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.